Biogen (BIIB) option IV into Clinical Trials on Alzheimer's Congress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) December weekly option implied volatility is at 55, December is at 51; compared to its 52-week range of 29 to 97 into data will be peer reviewed and presented Nov. 29 at the Clinical Trials on Alzheimer's Congress.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eaton (ETN) spreaders of November 6 weekly 397.50, November 6 weekly 440, November 420 and November 470 calls as share price down 7%
- Groupon (GRPN) spreaders of November 22, December 22, January 20 calls
- Biogen (BIIB) PT Raised to $244 at BofA Securities
Create E-mail Alert Related Categories
OptionsRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
